Press Releases

 
Press Releases
  Date Title View
Mar 19, 2015
LEXINGTON, Mass., March 19, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its financial results for the full year ended December 31, 2014. Recent Highlights Opened enrollmen...
PDF
Mar 17, 2015
LEXINGTON, Mass., March 17, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has opened enrollment for its Phase II clinical trial of NS2 for patients with Sjögren-Larsson Syndrome. ...
PDF
Mar 10, 2015
LEXINGTON, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the fourth quarter and twelve months ended December 31, 2014 on Thursday, Ma...
PDF
Mar 2, 2015
LEXINGTON, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today provided an update on its planned clinical trial programs in noninfectious anterior uveitis and Sjögren-Larsson Syndrome, as pa...
PDF
Feb 23, 2015
LEXINGTON, Mass., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present a corporate overview at the 35th Annual Cowen ...
PDF
Feb 2, 2015
LEXINGTON, Mass., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on its lead product candidate, NS2, has been accepted for two poster presentations at the upcoming Associat...
PDF
Jan 29, 2015
LEXINGTON, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on the potential of its lead product candidate, NS2, to treat Sjögren-Larsson Syndrome (SLS) has been...
PDF
Jan 26, 2015
LEXINGTON, Mass., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer and Mr. Stephen Tulipano, Chief Financial Officer o...
PDF
Jan 22, 2015
LEXINGTON, Mass., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the closing of its previously announced $2.0 million private placement of common stock and a warrant to purchase common st...
PDF
Jan 20, 2015
LEXINGTON, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement with a leading financial services company to raise approximately ...
PDF
Page: FirstPrevious ...
9
NextLast